Genetics Branch, Molecular Targets Core, CCR
National Cancer Institute
United States of America
Dr. Cao received his Ph.D. from the Department of Biochemistry and Molecular Biology at Harvard University in 1991. Subsequently, he was a Damon Runyon Cancer Research Fellow at the Cancer Center of Massachusetts General Hospital. He has managed research and drug discovery operations in academic and industry labs for 17 years. He is an inventor of over 30 US patents that resulted in novel diagnostics, drug discovery products, and therapeutic molecules in clinical trials.
1) Identification of predictive biomarkers, 2) Biomarker assay development and validation, 3) Biomarker analysis and correlative studies, 4) Molecular pathogenesis of pediatric sarcoma, 5) Preclinical evaluation of novel targeted therapies and identification of predictive biomarkers to be implemented for clinical investigations, 6) Cancer Biology, 7) Cell Biology, 8) Molecular Pharmacology